We still don't have comprehensive medical countermeasures
In the eastern reaches of the Democratic Republic of Congo, a rare strain of Ebola — one for which no approved vaccine exists — has claimed more than 200 lives and touched over 850 suspected cases, drawing humanitarian workers like MSF's Kate White into a landscape of compounding crises. The outbreak was already spreading before it was detected, leaving its transmission chains poorly mapped, while airspace closures and resource scarcity have made the work of containment feel like reasoning against the tide. This moment asks an older, harder question: why, after decades of recurring outbreaks, does the world still arrive unprepared to the same emergency?
- A rare Ebola strain with no approved vaccine is spreading through a conflict-fractured region, leaving responders without one of their most essential tools.
- Airspace closures are blocking the movement of protective gear, testing kits, and medical personnel into affected areas at the very moment demand is most acute.
- The outbreak went undetected long enough that its transmission chains remain poorly understood, making targeted containment nearly impossible.
- Without rapid diagnostic capacity, patients who may not have Ebola are being held in treatment centres for days or weeks, separated from their families and consuming scarce resources.
- MSF teams are pressing for expanded diagnostic infrastructure across all affected zones — not only to track the virus, but to restore basic human dignity to those caught in the system.
Kate White was boarding a flight from Manchester on a Sunday morning, heading toward an Ebola outbreak that already felt different from the ones she had worked before. As a programme manager for Médecins Sans Frontières with years of field experience, she was not hiding her alarm. More than 200 people had died, over 850 suspected cases had been recorded, and the strain circulating in the DRC had no approved vaccine — only experimental candidates still far from the people who needed them. "It says something about the state of the world right now," she said, that after so many outbreaks, comprehensive medical countermeasures still did not exist.
The logistical picture was equally grim. Airspace closures had turned the movement of healthcare workers and supplies into an unsolvable puzzle. The volume of what needed to reach affected areas — protective equipment, testing kits, medicines — was immense, and the routes to deliver it were closing. Compounding this was a painful epidemiological blind spot: the outbreak had been spreading for some time before detection, leaving its transmission chains murky and its containment far more difficult.
Inside the treatment centres, a quieter crisis was unfolding. Without rapid diagnostic capability across all affected zones, people who did not have Ebola were being held in isolation for days or weeks, waiting for confirmation, separated from their families. White's concern was not only clinical — it was about human dignity. Getting people home safely, quickly, required testing infrastructure that simply was not there yet.
Ebola spreads through contact with infected bodily fluids and can take up to three weeks to show symptoms, beginning with fever and exhaustion before progressing to more severe illness. The virus normally lives in animals, but urbanisation has narrowed the distance between human populations and those natural reservoirs. In a region already fractured by conflict, the standard tools of outbreak response — rapid case identification, contact tracing, isolation — were harder to deploy than ever. White was flying into that reality, carrying the weight of what the world had still not learned to prevent.
Kate White was boarding a flight from Manchester on a Sunday morning, heading toward one of the world's most dangerous epidemics. As a programme manager for Médecins Sans Frontières, she had done this before—worked through previous Ebola outbreaks across Africa. But this time felt different, and she was not hiding her worry. "I'm extremely concerned about the inability to get resources" to the Democratic Republic of Congo, she said before departure. The outbreak unfolding there had already claimed more than 200 lives and generated over 850 suspected cases, and the machinery to fight it was already grinding against its limits.
What made this outbreak particularly vicious was its rarity. The strain circulating in the DRC had no approved vaccine. Experimental ones were in development somewhere in the world's research labs, but they were not here, not now, not available to the people who needed them. White, who comes from York and has spent years in the field during previous epidemics, found this gap almost incomprehensible. "In terms of how many years we have been seeing these outbreaks," she said, "and we still don't have comprehensive medical countermeasures—treatment, vaccines, diagnostic testing that can be rolled out rapidly—it says something about the state of the world right now."
The logistics were crushing. Airspace closures meant that getting healthcare workers and equipment into affected areas had become a puzzle with no clean solution. The sheer volume of what needed to move—protective gear, testing kits, medical supplies—was staggering. White kept returning to this point: "The pure volume of what we need to get in right now is massive." It was not abstract concern. It was the weight of real constraints meeting real need.
But there was another problem, one that spoke to how far behind the world still was in controlling these diseases. The outbreak had been spreading for a substantial period before anyone detected it. That delay meant the chains of transmission remained murky. Nobody fully understood how the virus was moving through the population. "When we don't fully understand that," White explained, "it becomes much more difficult to get it under control." It was like trying to stop a fire when you could not see where it had started.
One immediate crisis was unfolding in the treatment centres themselves. Without rapid diagnostic capability across all the affected areas, people were getting stuck in these facilities even when they did not have Ebola. They were isolated from their families, consuming resources, waiting for confirmation that might take days or weeks. "We want to be able to discharge them as soon as they recover," White said, "so they can go back to their families." But the testing infrastructure was not there yet. Improving the ability to confirm cases quickly, across every geographic area where the virus was spreading, had become urgent not just for epidemiology but for basic human dignity.
Ebola itself moves through contact with infected bodily fluids—blood, vomit, sweat. It starts like flu or malaria, with fever and exhaustion, then progresses to vomiting and diarrhoea, sometimes organ failure, sometimes bleeding inside and out. It takes two to three weeks for symptoms to show. The virus normally lives in animals, but urbanisation has pushed human populations closer to those natural reservoirs, and the risk of spillover keeps climbing. This particular outbreak was happening in a region already fractured by conflict, which meant the usual tools of outbreak response—rapid case identification, contact tracing, isolation—were harder to deploy.
White was flying into that reality. She knew what she would find: a healthcare system under siege, resources stretched past breaking, a rare virus with no vaccine, and the clock running. The world had seen Ebola before. It had not learned to stop it.
Citas Notables
I'm extremely concerned about the inability to get resources to the Democratic Republic of Congo— Kate White, MSF programme manager
The pure volume of what we need to get in right now is massive— Kate White, MSF programme manager
La Conversación del Hearth Otra perspectiva de la historia
Why does the lack of a vaccine matter so much if you have other tools—isolation, treatment, contact tracing?
Because those tools only work if you can deploy them fast and completely. Without a vaccine, every case is a potential chain reaction. You're always playing catch-up, always behind the virus.
She mentioned the outbreak had been spreading for a while before detection. How much does that delay actually cost?
Everything. If you don't know where it started, you don't know who was exposed. You're treating people who might not have it, missing people who do. The transmission chains become invisible.
The airspace closures—is that a safety measure or something else?
It's meant to be safety, to prevent spread. But it's a blunt instrument. It keeps out the very people and supplies you need to fight the outbreak. It's a paradox that kills people.
She seemed frustrated about diagnostic testing. What's the actual bottleneck there?
Speed and geography. You need tests that work in field conditions, in remote areas, with results in hours not days. And you need them everywhere at once. That infrastructure doesn't exist yet.
Is there any reason to think this outbreak will be different from previous ones?
The conflict in the region makes it harder. The rare strain means no vaccine. The urbanisation means more people at risk. No—this one looks worse.